The Biologics Innovation Accelerator: Concept to Commercial

Overview

When we started our partnership with Syngene, they were already known as one of the world’s top two CROs — a true chemistry and biology powerhouse. But Syngene was now investing heavily in CDMO services and needed to build trust, particularly around commercial biologics delivery.

How Did We Do That?

We knew we had to fundamentally shift how the market saw Syngene — from being a top CRO advancing targets through discovery to becoming one of the world’s only end-to-end CRDMOs.

With the BIOSECURE Act and growing debates about supply chain flexibility, the timing was perfect — but we needed big pharma customers to recognise Syngene not just as a viable commercial supply option, but as their preferred partner.

Our strategy:

• Leaned into debates about alternative sourcing and used them to reposition Syngene as the natural choice for pharma companies seeking to diversify away from China.
• Launched a major thought leadership campaign to put Syngene at the centre of the conversation.
• Shifted the BIOSECURE narrative to highlight why this moment represented a massive opportunity for India — focusing media attention on Syngene’s quality, scale, and end-to-end capabilities.
• Generated consistent news flow with a series of timed updates to tell the story of a rising commercial biologics CDMO.

Our challenge was clear: get this story in front of the people who matter most — the heads of outsourcing and external manufacturing at big pharma.

Results

• 46 long-form thought leadership placements in pharma media — the most of any CDMO in 2024.
• Despite having far fewer “hard news” events (acquisitions, M&A, etc.), Syngene was the 3rd most covered CDMO for news thanks to consistent story generation.
• Widely identified as a big winner of macro sourcing shifts and credited with gaining major US commercial supply deals.
• The most interviewed CDMO in 2024, with 22 in-person media interviews — a transformative moment in helping the media understand Syngene’s brand and value to pharma.

So it’s no surprise that today its winning strategic partnerships, attracting commercial interest, and investing in new capacity to keep pace with industry demand